How Publishers Handle Retractions: What the 2026 Analysis Means for Medical Authors

Most researchers treat retraction as something that happens to other people's papers. It is worth checking that assumption. In 2023, publishers issued more than 14,000 retraction notices, a figure that has surprised even researchers who follow these trends closely. The total declined somewhat in 2024 and 2025, but retraction volumes remain historically high, and the underlying pressures driving them have not gone away. What is less understood is that how journals and publishers respond to integrity concerns varies enormously, in ways that directly affect authors whose papers are either the subject of a retraction request or cited from already-retracted work.

A February 2026 preprint analyzed 46,087 retractions across ten major publishers using data from the Retraction Watch database spanning 1997 to 2026. The findings are striking. Normalized retraction rates vary by two orders of magnitude, from Elsevier's 3.97 per 10,000 publications to Hindawi's 320.02. Even excluding the obvious outlier, SAGE came in at 5.46, Wiley at 6.21, Taylor and Francis at 6.50, and Springer Nature at 9.06. PLOS, whose flagship journals have long emphasized research integrity, came in at 26.82. The differences do not map neatly onto which publishers have the most fraudulent authors. They map onto different editorial cultures, different investment in detection, and markedly different appetites for acting on what is found.

Why Retraction Rates Cannot Be Taken at Face Value

The instinctive interpretation of a low retraction rate is that a publisher produces cleaner research. This interpretation is almost certainly wrong, and the 2026 analysis provides the clearest evidence yet for why. A low retraction rate can mean that a publisher conducts thorough pre-publication screening, catches problems before they reach print, and avoids publishing the kind of volume-driven, fast-turnaround work that correlates with misconduct. It can also mean that a publisher has invested very little in post-publication integrity review, does not respond promptly to reader concerns, and has a culture of protecting its relationship with authors over correcting the record.

Elsevier's position is the clearest illustration of this ambiguity. At 3.97 retractions per 10,000 publications, Elsevier has the lowest normalized rate in the analysis, yet it also accounts for 86 of the 98 total article reinstatements across all publishers combined. That means Elsevier reinstated 1.3 percent of its retracted articles following retraction. No other publisher came close. Reinstatement after retraction typically happens when an original retraction was issued incorrectly, in error, or after pressure from parties with an interest in the paper's continued status. A high reinstatement rate can suggest that some retractions were contested successfully, but it can also suggest that the initial retraction process was under-scrutinized.

Hindawi's rate of 320.02 per 10,000 tells a different and very specific story. Hindawi, which Wiley acquired and has been winding down, became one of the central cases in the paper mill crisis. Wiley retracted roughly 11,300 papers from Hindawi journals between 2023 and 2025, a batch retraction of a scale previously unseen in academic publishing. When you normalize Hindawi's output, the retraction rate approaches two orders of magnitude above publishers like Elsevier. That is not a sign of editorial integrity. It is a sign of what happens when volume-based publishing and weak editorial controls intersect with organized fraud.

What Publishers Are Actually Retracting For

The most common reasons for retraction across the ten publishers in the analysis were issues with results or conclusions, third-party involvement or concerns, plagiarism, data problems, and problematic peer review. Scientific misconduct broadly defined, including falsification, fabrication, and plagiarism, now accounts for roughly 60 percent of retraction notices issued, according to a separate analysis published in April 2026. This share has grown. In earlier decades, honest error and methodological problems made up a much larger fraction. The current composition reflects both a real increase in fraud and better detection tools.

Third-party involvement is a category worth understanding precisely. It covers cases where a paper mill was implicated, where purchased authorship was uncovered, where a reviewer fabricated credentials or reviews, or where a co-author was added to the paper without meaningful contribution. This category has grown sharply since 2020, driven largely by the paper mill investigations that have swept through oncology, cardiology, and materials science journals. A July 2026 Nature analysis screened 2.6 million cancer papers and found roughly one in ten may originate from paper mills. For retraction purposes, papers in this category are often retracted in batches rather than individually, which explains the spikes visible in the data for certain publishers in certain years.

PLOS's rate of 26.82 is conspicuous because PLOS does not primarily publish work from high-fraud-risk fields. Its higher rate largely reflects what happens when a publisher invests seriously in post-publication review. PLOS ONE, the megajournal that publishes across all of science and medicine based on methodological soundness rather than novelty, attracts a high volume of submissions and has correspondingly active reader and post-publication scrutiny. PLOS also has one of the longest median lags between publication and retraction: over four years. That long window means papers have time to accumulate citations before the problem is caught, which has implications for anyone relying on PLOS papers in a literature review.

The Time Gap Between Publication and Retraction

One finding from the analysis that deserves more attention from authors is the variation in the lag between when a paper is published and when it is retracted. This lag varies from weeks to years depending on the publisher, the reason for retraction, and whether the concern originated from the editorial team, from a reader, from a post-publication review service like Pubpeer, or from a formal investigation. PLOS's four-year median lag is longer than most publishers, but it is not an outlier in a meaningful way. Springer Nature and Taylor and Francis both show similar patterns in certain fields.

For authors, a long publication-to-retraction lag creates a particularly uncomfortable problem if the retracted paper has accumulated citations in your own prior work. You may have cited it in good faith and published before the retraction notice appeared. The paper is now part of your citation history even though it should not be, and the citation will persist unless you actively correct it. Checking your own prior citations against the Retraction Watch database is the only reliable way to catch this. The Crossref Retraction Watch API allows automated checking, and several reference managers now offer retraction alerts, but these tools are only as current as their underlying database and only flag papers that have been processed.

Who Bears the Cost of a Retraction

A 2025 Nature paper on the career effects of retractions found that the impact falls disproportionately on early-career researchers and on researchers in lower-income countries, even when the researcher was not the corresponding author and did not initiate the misconduct. When a paper is retracted, all authors take the hit in a publication record sense. Junior co-authors, who may have contributed honestly to a paper that was later found to have problems elsewhere in the authorship chain, face a correction to their record that they had no control over and may not have been informed of in advance.

The geographic concentration matters for another reason. Many paper mill operations have been traced to organizations in a handful of countries where academic promotion systems create extreme pressure to publish. Authors who buy authorship slots from mills are often doing so under institutional pressure, not purely out of personal greed. The resulting retractions then get distributed across all listed co-authors, including those who had nothing to do with the purchase. In the STOTEN case in August 2026, Elsevier retracted over 100 papers from its journal Science of the Total Environment for authorship irregularities and editor conflicts of interest, with most retractions covering articles published between 2018 and 2025. At least 50 of the retracted papers had been handled by associate editors who had ongoing active collaborations with the authors, raising the question of how the conflict went undetected during that entire period.

For medical authors, the career stakes are somewhat different from those in basic science. A retracted clinical paper carries particular weight because of its potential effect on medical practice. A retracted randomized controlled trial, a retracted meta-analysis, or a retracted pharmacokinetics study can continue to influence prescribing or clinical guidelines even after formal withdrawal. This is not hypothetical: the Surgisphere retractions of 2020 and subsequent investigations have documented how clinical guidance incorporated flawed data before the source papers were retracted. The medical literature's long-term record is thus not just an academic concern. It affects patients.

What COPE Requires of Publishers When They Retract

The Committee on Publication Ethics released Version 3 of its retraction guidelines in August 2025, adding explicit criteria for AI-related undisclosed use, paper mills, and batch retractions. Under COPE's guidance, journals should issue a retraction when findings are unreliable due to honest error or misconduct, when the work has been published elsewhere without proper citation, when authorship is fraudulent, when there is undisclosed conflict of interest, when peer review was manipulated, or when there is evidence the paper was produced by a paper mill. This is the formal standard, but actual practice varies significantly.

COPE does not have enforcement power. It can withdraw membership from a journal that consistently fails to meet its standards, but most of its influence is normative: journals that are COPE members signal they subscribe to the guidelines, and editors who follow COPE recommendations are acting within a recognized professional framework. The practical gap between what COPE requires and what journals actually do is documented in the 2026 analysis: retraction notices are frequently incomplete, lack the specific reason for retraction, omit the names of authors who agreed with the retraction versus those who did not, and are often published without any direct notification to databases where the paper is indexed.

One direct consequence is that PubMed, Scopus, and Web of Science do not always reflect a retraction promptly. Papers may remain untagged in PubMed for months after the journal has issued the notice. The Crossref Retraction Watch API attempts to address this with a daily-updated feed, but it depends on journals submitting retraction metadata correctly, which not all do. Authors checking their own citation lists need to use the Retraction Watch database directly, not rely on PubMed tagging alone.

What the Data Means for Where You Publish

The variation in publisher retraction practices creates a genuine consideration for authors deciding where to submit. This is not an argument for publishing with publishers that have low retraction rates. A very low rate can be a sign of under-detection or slow response rather than clean science. It is an argument for understanding what a publisher's retraction culture actually is before you submit, particularly if your work is in a field with a known paper mill problem.

For most medical authors, the relevant questions are simpler than the full publisher comparison suggests. Does the journal you are targeting have transparent retraction processes? Does it publish retraction notices promptly and with adequate detail? Does it respond to PubPeer concerns within a reasonable timeframe? Does it have a dedicated editorial integrity team or a mechanism for receiving and processing integrity concerns? Publishers like Springer Nature have over 75 full-time research integrity specialists. Others rely on editors handling concerns as they arise alongside a full editorial workload. Those are not equivalent systems.

Journals that belong to COPE and regularly audit their retraction notices for completeness are doing something meaningful, even if their retraction rate looks higher than a peer's. A journal that proactively identifies and retracts problematic work is cleaning the record. A journal with a vanishingly low retraction rate may be doing so because it is not looking.

If Your Paper Comes Under Scrutiny

Most authors whose papers are retracted are not the ones who committed fraud. They are co-authors of work that later came under scrutiny, or corresponding authors on papers where a junior member of the team fabricated a dataset, or researchers whose names were listed on papers purchased through a paper mill by an institutional collaborator they may barely know. The STOTEN case in 2026 illustrates this pattern precisely: many of the 100+ retracted papers had authors who were apparently unaware of the editorial conflict of interest that had contaminated their review.

If you receive a concern notice from a journal editor, the two things that matter most are response time and record-keeping. Respond to the editor's initial inquiry within the requested window, even if only to say you need more time to gather documents. Request the specific reason for the concern in writing. If the concern involves a dataset or figure that one of your co-authors prepared, contact that co-author and request the original files immediately, before the review progresses. Document your own contributions to the disputed element carefully. An expression of concern is not a retraction. A retraction notice may contain language about whether the retraction was agreed upon by all authors or imposed by the editors. Both can appear in the published retraction notice, and the distinction matters for how the event is read by future hiring committees or grant reviewers.

An Incomplete System Getting Incrementally Better

The 2026 retraction analysis was not designed as a ranking of publisher integrity. It was designed to describe the system as it actually operates, with all its variation and inconsistency. What it shows is that retraction is not a uniform mechanism. It is a collection of practices that differ by publisher, by journal within a publisher, by field, by geography, and by the nature of the concern. Authors who understand those differences are better positioned to respond when something goes wrong, and to evaluate journals on dimensions beyond headline metrics.

The retraction crisis, if we are calling it that, is partly a crisis of volume and partly a crisis of detection lag. Tools like Elsevier's Check Integrity platform, expanded to roughly 2,000 journals in March 2026, aim to catch integrity concerns before publication rather than after. Springer Nature's investment in full-time integrity staff represents a similar preventive orientation. The effect on retraction rates from these upstream interventions will take several years to show clearly in the data, because the papers whose problems they prevent never become retractions at all.

For medical authors, the most direct practical implication is this: know your publisher's retraction culture before you submit, check your own citation list against Retraction Watch before submission, and treat any post-publication integrity query as requiring an immediate, documented, and co-author-coordinated response. The papers that turn into retractions rather than corrections are usually those where the initial response was slow, disorganized, or defensive. The ones that become corrections or are resolved without public action are those where the authors responded promptly, provided documentation, and worked with the journal within its stated process. That is the part of retraction mechanics that is entirely within an author's control.

Further Reading